Instylla – a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy – recently announced the closing of a $30 million financing round. This funding round was led by new investor Delos Capital, with continued participation from the investor syndicate of Excelestar Ventures, Ascension Ventures, Catalyst Health Ventures, Amed Ventures, Sparta Group, and Incept, LLC.
The funds from this funding round are anticipated to see Instylla through the ongoing prospective clinical trials and early commercialization.
The Instylla HES Hypervascular Tumor Pivotal Study is now enrolling patients in the US and Canada to evaluate the safety and effectiveness of the Instylla Hydrogel Embolic System (HES) compared with standard of care transcatheter arterial embolization or transcatheter arterial chemoembolization for the vascular occlusion of hypervascular tumors. And the “HALT” Study was recently launched in the US and is continuing to enroll patients to study the safety and effectiveness of Embrace HES for the embolization of arterial bleeding in solid organs and peripheral arteries.
KEY QUOTES:
“At Instylla, we are executing two large pivotal clinical trials in North America in pursuit of our two initial indications for the embolization of hypervascular tumors and peripheral arterial bleeds. The funds will allow us to complete the clinical trials and prepare for the commercialization of Embrace HES. We are excited to have Delos Capital join our strong group of healthcare investors who share our values.”
— Amar Sawhney, CEO of Instylla, Inc. and Managing Director of Incept, LLC
“Instylla has demonstrated impressive progress, having already advanced its next-generation liquid embolic technology to human clinical studies. We are honored and thrilled to support Instylla as it continues developing breakthrough solutions that will meaningfully improve patient outcomes.”
— Henry Chen, Managing Partner, Delos Capital – who has joined the Instylla Board of Directors
